I don't buy the argument that Peregrine should, or that it is, totally focused on Bavituximab's cancer indications. The company employs around 180 individuals, each one available to team up and execute on their applicable skill set.
If Bavituximab is particularly effective on Ebola, HIV, or a dozen other viruses then work done is those areas hardly qualifies as a distraction.
I am impressed with the quality and quantity of Peregrine management's achievements. I am distressed by Peregrine's treatment of its shareholders. Shareholders work hard for our money, so hard for it honey. We work hard for our money so you better treat us right.
PPHM, THE COMPANY THAT'S LIKE KALE. IMHO